273 related articles for article (PubMed ID: 18543281)
1. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
Mouraviev V; Mayes JM; Sun L; Madden JF; Moul JW; Polascik TJ
Cancer; 2007 Aug; 110(4):906-10. PubMed ID: 17587207
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
4. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
Freedland SJ; Partin AW; Epstein JI; Walsh PC
Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
[TBL] [Abstract][Full Text] [Related]
5. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort.
Tareen B; Sankin A; Godoy G; Temkin S; Lepor H; Taneja SS
Urology; 2009 Feb; 73(2):351-4; discussion 354-5. PubMed ID: 19038430
[TBL] [Abstract][Full Text] [Related]
6. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
[TBL] [Abstract][Full Text] [Related]
7. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
[TBL] [Abstract][Full Text] [Related]
8. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
10. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
11. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
[TBL] [Abstract][Full Text] [Related]
12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
13. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.
Desireddi NV; Roehl KA; Loeb S; Yu X; Griffin CR; Kundu SK; Han M; Catalona WJ
Urology; 2007 Nov; 70(5):950-5. PubMed ID: 18068453
[TBL] [Abstract][Full Text] [Related]
14. There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies.
Briganti A; Tutolo M; Suardi N; Gallina A; Abdollah F; Capitanio U; Freschi M; Bianchi M; Salonia A; Colombo R; Rigatti P; Montorsi F
Prostate; 2012 Jun; 72(8):925-30. PubMed ID: 21965006
[TBL] [Abstract][Full Text] [Related]
15. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
16. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
[TBL] [Abstract][Full Text] [Related]
18. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
19. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy.
Guzzo TJ; Vira MA; Neway W; Hwang WT; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz SB
Urology; 2007 Jun; 69(6):1147-51. PubMed ID: 17572204
[TBL] [Abstract][Full Text] [Related]
20. Body mass index trends and role of obesity in predicting outcome after radical prostatectomy.
Motamedinia P; Korets R; Spencer BA; Benson MC; McKiernan JM
Urology; 2008 Nov; 72(5):1106-10. PubMed ID: 18602142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
